

References

1. Kalichman SC, Belcher L, Cherry C, Williams E. Primary prevention of sexually transmitted HIV infections: transferring behavioral research to community programs. *J Prim Prev.* 1997;18:149–72.
2. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. *Lancet.* 1994;344(8917):243–5. Epub 23 July 1994.
3. Stoneburner RL, Low-Beer D. Sexual partner reductions explain human immunodeficiency virus declines in Uganda: comparative analyses of HIV and behavioural data in Uganda, Kenya, Malawi, and Zambia. *Int J Epidemiol.* 2004;33(3):624. Epub 12 June 2004.
4. Slutkin G, Okware S, Naamara W, Sutherland D, Flanagan D, Carael M, et al. How Uganda reversed its HIV epidemic. *AIDS Behav.* 2006;10(4):351–60. Epub 22 July 2006.
5. Merson M. Uganda's HIV/AIDS Epidemic: Guest Editorial. *AIDS Behav.* 2006;10:333–4.
6. Skoler-Karppoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008;372(9654):1977–87. Epub 9 Nov 2008.
7. Dunne EF, Whitehead S, Sternberg M, Thepamnuay S, Leelawiwat W, McNicholl JM, et al. Suppressive acyclovir therapy reduces HIV cervicovaginal shedding in HIV- and HSV-2-infected women, Chiang Rai, Thailand. *J Acquir Immune Defic Syndr.* 2008;49(1):77–83. Epub 1 Aug 2008.
8. Celum C, Wald A, Hughes J, Sanchez J, Reid S, Delany-Moretlwe S, et al. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008;371(9630):2109–19. Epub 24 June 2008.
9. Watson-Jones D, Weiss HA, Rusizoka M, Chagalucha J, Baisley K, Mugeye K, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. *N Engl J Med.* 2008;358(15):1560–71. Epub 14 Mar 2008.
10. El-Bassel N, Jemmott JB, Landis JR, Pequegnat W, Wingood GM, Wyatt GE, et al. National Institute of Mental Health Multisite Eban HIV/STD Prevention Intervention for African American HIV Serodiscordant Couples: a cluster randomized trial. *Arch Intern Med.* 2010;170(17):1594–601. Epub 14 July 2010.
11. Hallett TB, Singh K, Smith JA, White RG, Abu-Raddad LJ, Garnett GP. Understanding the impact of male circumcision interventions on the spread of HIV in southern Africa. *PLoS One.* 2008;3(5):e2212. Epub 22 May 2008.
12. Williams BG, Lloyd-Smith JO, Gouws E, Hankins C, Getz WM, Hargrove J, et al. The potential impact of male circumcision on HIV in Sub-Saharan Africa. *PLoS Med.* 2006;3(7):e262. Epub 11 July 2006.

13. Noar SM. Behavioral interventions to reduce HIV-related sexual risk behavior: review and synthesis of meta-analytic evidence. *AIDS Behav.* 2008;12(3):335–53. Epub 27 Sept 2007.
14. Scott-Sheldon LA, Huedo-Medina TB, Warren MR, Johnson BT, Carey MP. Efficacy of behavioral interventions to increase condom use and reduce sexually transmitted infections: a meta-analysis, 1991 to 2010. *J Acquir Immune Defic Syndr.* 2011;58(5):489–98. Epub 16 Nov 2011.
15. Scott-Sheldon LA, Fielder RL, Carey MP. Sexual risk reduction interventions for patients attending sexually transmitted disease clinics in the United States: a meta-analytic review, 1986 to early 2009. *Ann Behav Med.* 2010;40(2):191–204. Epub 24 July 2010.
16. Lagakos SW, Gable AR. Challenges to HIV prevention—seeking effective measures in the absence of a vaccine. *N Engl J Med.* 2008;358(15):1543–5. Epub 12 Apr 2008.
17. Padian NS, McCoy SI, Balkus JE, Wasserheit JN. Weighing the gold in the gold standard: challenges in HIV prevention research. *AIDS.* 2010;24(5):621–35. Epub 25 Feb 2010.
18. Padian NS, van der Straten A, Ramjee G, Chipato T, de Bruyn G, Blanchard K, et al. Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. *Lancet.* 2007;370(9583):251–61. Epub 17 July 2007.
19. Koblin B, Chesney M, Coates T. Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. *Lancet.* 2004;364(9428):41–50. Epub 6 July 2004.
20. Chesney MA, Koblin BA, Barresi PJ, Husnik MJ, Celum CL, Colfax G, et al. An individually tailored intervention for HIV prevention: baseline data from the EXPLORE Study. *Am J Public Health.* 2003;93(6):933–8. Epub 30 May 2003.
21. Kamb M, Fishbein M, Douglas J, Rhodes F, Rogers J, Bolan G, et al. Efficacy of risk-reduction counseling to prevent Human Immunodeficiency Virus and Sexually Transmitted Diseases. *J Am Med Assoc.* 1998;280(13):1161–7.
22. Chesney, M, Coates, T, Koblin, B. A randomized clinical trial of the efficacy of a behavioral intervention to prevent acquisition of HIV among men who have sex with men: HIVNET Protocol No. 015. Available from http://www.hptn.org/research_studies/HIVNET015StudyDocuments.htm.
23. Stall R, Duran L, Wisniewski SR, Friedman MS, Marshal MP, McFarland W, et al. Running in place: implications of HIV incidence estimates among urban men who have sex with men in the United States and other industrialized countries. *AIDS Behav.* 2009;13(4):615–29. Epub 12 Feb 2009.
24. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. *J Acquir Immune Defic Syndr.* 2006; 41(3):285–97. Epub 17 Mar 2006.
25. Simoni JM, Amico KR, Pearson CR, Malow R. Strategies for promoting adherence to antiretroviral therapy: a review of the literature. *Curr Infect Dis Rep.* 2008;10(6):515–21. Epub 24 Oct 2008.
26. Simoni JM, Frick PA, Pantalone DW, Turner BJ. Antiretroviral adherence interventions: a review of current literature and ongoing studies. *Top HIV Med.* 2003;11(6):185–98. Epub 16 Jan 2004.
27. Parienti JJ, Das-Douglas M, Massari V, Guzman D, Deeks SG, Verdon R, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-to-moderate adherence levels. *PLoS One.* 2008;3(7):e2783. Epub 31 July 2008.
28. DiIorio C, McCarty F, Resnicow K, McDonnell Holstad M, Soet J, Yeager K, et al. Using motivational interviewing to promote adherence to antiretroviral medications: a randomized controlled study. *AIDS Care.* 2008;20(3):273–83. Epub 21 Mar 2008.
29. DiIorio C, Resnicow K, McDonnell M, Soet J, McCarty F, Yeager K. Using motivational interviewing to promote adherence to antiretroviral medications: a pilot study. *J Assoc Nurses AIDS Care.* 2003;14(2):52–62. Epub 18 Apr 2003.
30. de Bruin M, Viechtbauer W, Hospers HJ, Schaalma HP, Kok G. Standard care quality determines treatment outcomes in control groups of HAART-adherence intervention studies: implications for the interpretation and comparison of intervention effects. *Health Psychol.* 2009;28(6):668–74. Epub 18 Nov 2009.

31. Amico KR. Standard of care for antiretroviral therapy adherence and retention in care from the perspective of care providers attending the 5th international conference on HIV treatment adherence. *J Int Assoc Physicians AIDS Care (Chic)*. 2011;10(5):291–6. Epub 12 May 2011.
32. Rotheram-Borus MJ, Ingram BL, Swendeman D, Flannery D. Common principles embedded in effective adolescent HIV prevention programs. *AIDS Behav*. 2009;13(3):387–98. Epub 19 Feb 2009.
33. Rotheram-Borus MJ, Swendeman D, Flannery D, Rice E, Adamson DM, Ingram B. Common factors in effective HIV prevention programs. *AIDS Behav*. 2009;13(3):399–408. Epub 3 Oct 2008.
34. Ingram BL, Flannery D, Elkavich A, Rotheram-Borus MJ. Common processes in evidence-based adolescent HIV prevention programs. *AIDS Behav*. 2008;12(3):374–83. Epub 12 Mar 2008.
35. Cassell MM, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovations in HIV prevention? *BMJ*. 2006;332(7541):605–7. Epub 11 Mar 2006.
36. Phillips KA, Coates TJ. HIV counselling and testing: research and policy issues. *AIDS Care*. 1995;7(2):115–24. Epub 1 Jan 1995.
37. Bogard E, Kuntz KM. The impact of a partially effective HIV vaccine on a population of intravenous drug users in Bangkok, Thailand: a dynamic model. *J Acquir Immune Defic Syndr*. 2002;29(2):132–41. Epub 8 Feb 2002.
38. Crosby RA, Holtgrave DR. Will sexual risk behaviour increase after being vaccinated for AIDS? *Int J STD AIDS*. 2006;17(3):180–4. Epub 3 Mar 2006.
39. Pinkerton SD. Sexual risk compensation and HIV/STD transmission: empirical evidence and theoretical considerations. *Risk Anal*. 2001;21(4):727–36. Epub 1 Dec 2001.
40. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomized controlled trial. *Lancet*. 2007;369:643–56.
41. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. *Curr HIV/AIDS Rep*. 2007;4:165–72.
42. Kalichman S, Eaton L, Pinkerton S. Circumcision for HIV prevention: failure to fully account for behavioral risk compensation. *PLoS Med*. 2007;4(3):e138. author reply e46. Epub 29 Mar 2007.
43. Eaton L, Kalichman SC. Behavioral aspects of male circumcision for the prevention of HIV infection. *Curr HIV/AIDS Rep*. 2009;6(4):187–93. Epub 24 Oct 2009.
44. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. *Science*. 2010;329(5996):1168–74. Epub 21 July 2010.
45. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. *N Engl J Med*. 2010;363(27):2587–99. Epub 26 Nov 2010.
46. Weinhardt LS, Mosack KE, Swain GR. Development of a computer-based risk-reduction counseling intervention: acceptability and preferences among low-income patients at an urban sexually transmitted infection clinic. *AIDS Behav*. 2007;11(4):549–56. Epub 10 Oct 2006.
47. Grimley DM, Hook 3rd EW. A 15-minute interactive, computerized condom use intervention with biological endpoints. *Sex Transm Dis*. 2009;36(2):73–8. Epub 7 Jan 2009.
48. Bellis JM, Grimley DM, Alexander LR. Feasibility of a tailored intervention targeting STD-related behaviors. *Am J Health Behav*. 2002;26(5):378–85. Epub 11 Sept 2002.
49. Fisher JD, Amico KR, Fisher WA, Cornman DH, Shuper PA, Trayling C, et al. Computer-based intervention in HIV clinical care setting improves antiretroviral adherence: the LifeWindows Project. *AIDS Behav*. 2011;15(8):1635–46. Epub 1 Apr 2011.
50. Reynolds NR, Testa MA, Su M, Chesney MA, Neidig JL, Frank I, et al. Telephone support to improve antiretroviral medication adherence: a multisite, randomized controlled trial. *J Acquir Immune Defic Syndr*. 2008;47(1):62–8. Epub 25 Sept 2007.

51. Senore C, Giordano L, Bellisario C, Di Stefano F, Segnan N. Population based cancer screening programmes as a teachable moment for primary prevention interventions. A review of the literature. *Front Oncol.* 2012;2:45. Epub 1 June 2012.
52. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of teachable moments: the case of smoking cessation. *Health Educ Res.* 2003;18(2):156–70. Epub 6 May 2003.
53. McBride CM, Ostroff JS. Teachable moments for promoting smoking cessation: the context of cancer care and survivorship. *Cancer Control.* 2003;10(4):325–33. Epub 14 Aug 2003.
54. UNAIDS. Combination HIV prevention: tailoring and coordinating biomedical, behavioural and structural strategies to reduce new HIV infections: a UNAIDS discussion paper. Geneva, Switzerland, 2010.
55. Coates TJ, Richter L, Caceres C. Behavioural strategies to reduce HIV transmission: how to make them work better. *Lancet.* 2008;372(9639):669–84. Epub 9 Aug 2008.
56. Tatoud RJ. Metaphors of HIV prevention: 1. The HIV prevention buffet. 2011 [cited 2012]. <http://www.incidence0.org/2011/05/31/metaphors-of-hiv-prevention-1-the-hiv-prevention-buffet/>.
57. Palmateer N, Kimber J, Hickman M, Hutchinson S, Rhodes T, Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. *Addiction.* 2010;105(5):844–59. Epub 12 Mar 2010.
58. Hyshka E, Strathdee S, Wood E, Kerr T. Needle exchange and the HIV epidemic in Vancouver: lessons learned from 15 years of research. *Int J Drug Policy.* 2012. Epub 15 May 2012.
59. Gillies M, Palmateer N, Hutchinson S, Ahmed S, Taylor A, Goldberg D. The provision of non-needle/syringe drug injecting paraphernalia in the primary prevention of HCV among IDU: a systematic review. *BMC Public Health.* 2010;10:721. Epub 26 Nov 2010.
60. Kalichman SC, Kelly JA, Sikkema KJ, Koslov AP, Shaboltas A, Granskaya J. The emerging AIDS crisis in Russia: review of enabling factors and prevention needs. *Int J STD AIDS.* 2000;11(2):71–5. Epub 4 Mar 2000.
61. Tobin KE, Muessig KE, Latkin CA. HIV seropositive drug users' attitudes towards partner notification (PCRS): results from the SHIELD study in Baltimore, Maryland. *Patient Educ Couns.* 2007;67(1–2):137–42. Epub 24 Apr 2007.
62. Latkin CA, Sherman S, Knowlton A. HIV prevention among drug users: outcome of a network-oriented peer outreach intervention. *Health Psychol.* 2003;22(4):332–9. Epub 28 Aug 2003.
63. Purcell DW, Metsch LR, Latka M, Santibanez S, Gomez CA, Eldred L, et al. Interventions for seropositive injectors-research and evaluation: an integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. *J Acquir Immune Defic Syndr.* 2004;37 Suppl 2:S110–8. Epub 24 Sept 2004.
64. Knowlton AR, Hua W, Latkin C. Social support networks and medical service use among HIV-positive injection drug users: implications to intervention. *AIDS Care.* 2005;17(4):479–92. Epub 23 July 2005.
65. Latkin CA, Donnell D, Metzger D, Sherman S, Aramrattna A, Davis-Vogel A, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. *Soc Sci Med.* 2009;68(4):740–8. Epub 17 Dec 2008.
66. Tobin KE, Hua W, Costenbader EC, Latkin CA. The association between change in social network characteristics and non-fatal overdose: results from the SHIELD study in Baltimore, MD, USA. *Drug Alcohol Depend.* 2007;87(1):63–8. Epub 12 Sept 2006.
67. Latkin CA, Davey MA, Hua W. Social context of needle selling in Baltimore, Maryland. *Subst Use Misuse.* 2006;41(6–7):901–13. Epub 1 July 2006.
68. Friedman SR, Bolyard M, Mateu-Gelabert P, Goltzman P, Pawlowicz MP, Singh DZ, et al. Some data-driven reflections on priorities in AIDS network research. *AIDS Behav.* 2007;11(5):641–51. Epub 21 Oct 2006.
69. Friedman SR, Mateu-Gelabert P, Curtis R, Maslow C, Bolyard M, Sandoval M, et al. Social capital or networks, negotiations, and norms? A neighborhood case study. *Am J Prev Med.* 2007;32(6 Suppl):S160–70. Epub 19 Aug 2007.

70. Kost K, Singh S, Vaughan B, Trussell J, Bankole A. Estimates of contraceptive failure from the 2002 National Survey of Family Growth. *Contraception*. 2008;77(1):10–21. Epub 18 Dec 2007.
71. Crosby RA, Diclemente RJ, Wingood GM, Salazar LF, Rose E, Levine D, et al. Correlates of condom failure among adolescent males: an exploratory study. *Prev Med*. 2005;41(5–6):873–6. Epub 1 Nov 2005.
72. Kalichman SC, Simbayi LC, Cain D, Jooste S. Condom failure among men receiving sexually transmissible infection clinic services, Cape Town, South Africa. *Sex Health*. 2009;6(4):300–4. Epub 18 Nov 2009.
73. Chow EP, Wilson DP, Zhang L. Patterns of condom use among men who have sex with men in China: a systematic review and meta-analysis. *AIDS Behav*. 2012;16(3):653–63. Epub 5 Apr 2011.
74. Kelly JA, Kalichman SC. Increased attention to human sexuality can improve HIV/AIDS prevention efforts: key research issues and directions. *J Consult Clin Psychol*. 1995;63(6):907–18. Epub 1 Dec 1995.
75. Koop CE. The early days of AIDS, as I remember them. *Ann Forum Collab HIV Res*. 2011;13:5–10.
76. Trenholm C, Devaney B, Fortson K, Clark M, Bridgespan LQ, Wheeler J. Impacts of abstinence education on teen sexual activity, risk of pregnancy, and risk of sexually transmitted diseases. *J Policy Anal Manage*. 2008;27(2):255–76. Epub 12 Apr 2008.
77. Jemmott 3rd JB, Jemmott LS, Fong GT. Abstinence and safer sex HIV risk-reduction interventions for African American adolescents: a randomized controlled trial. *JAMA*. 1998;279(19):1529–36. Epub 30 May 1998.
78. Barnett T, Parkhurst J. HIV/AIDS: sex, abstinence, and behaviour change. *Lancet Infect Dis*. 2005;5(9):590–3. Epub 27 Aug 2005.
79. Lyles CM, Kay LS, Crepaz N, Herbst JH, Passin WF, Kim AS, et al. Best-evidence interventions: findings from a systematic review of HIV behavioral interventions for US populations at high risk, 2000–2004. *Am J Public Health*. 2007;97(1):133–43. Epub 2 Dec 2006.
80. Nelson KE, Celentano DD, Eiumtrakol S, Hoover DR, Beyrer C, Suprasert S, et al. Changes in sexual behavior and a decline in HIV infection among young men in Thailand. *N Engl J Med*. 1996;335(5):297–303. Epub 1 Aug 1996.
81. Rojanapithayakorn W, Hanenberg R. The 100% condom program in Thailand. *AIDS*. 1996;10(1):1–7. Epub 1 Jan 1996.
82. National Institutes of Health. NIH Consensus Statement: Interventions to Prevent HIV Risk Behavior. 15(2), February 11–13, 1997. Available at <http://consensus.nih.gov/1997/1997PreventHIVRisk104PDF.pdf>.
83. Wingood GM, DiClemente RJ, Mikhail I, Lang DL, McCree DH, Davies SL, et al. A randomized controlled trial to reduce HIV transmission risk behaviors and sexually transmitted diseases among women living with HIV: The WiLLOW Program. *J Acquir Immune Defic Syndr*. 2004;37 Suppl 2:S58–67. Epub 24 Sept 2004.
84. Sandoy IF, Zyaambo C, Michelo C, Fylkesnes K. Targeting condom distribution at high risk places increases condom utilization—evidence from an intervention study in Livingstone, Zambia. *BMC Public Health*. 2012;12:10. Epub 10 Jan 2012.
85. Kenya: Female Condom Shortage. *Humanitarian news and analysis*. 2009.
86. Cecil H, Pinkerton SD, Bogart LM. Perceived benefits and barriers associated with the female condom among African-American adults. *J Health Psychol*. 1999;4(2):165–75. Epub 1 Mar 1999.
87. Gallo MF, Kilbourne-Brook M, Coffey PS. A review of the effectiveness and acceptability of the female condom for dual protection. *Sex Health*. 2012;9(1):18–26. Epub 22 Feb 2012.
88. Beksinska ME, Smit JA, Mantell JE. Progress and challenges to male and female condom use in South Africa. *Sex Health*. 2012;9(1):51–8. Epub 22 Feb 2012.
89. Kelvin EA, Mantell JE, Candelario N, Hoffman S, Exner TM, Stackhouse W, et al. Off-label use of the female condom for anal intercourse among men in New York City. *Am J Public Health*. 2011;101(12):2241–4. Epub 25 Oct 2011.

90. Kalichman SC, Rompa D, Cage M. Factors associated with female condom use among HIV-seropositive women. *Int J STD AIDS*. 2000;11(12):798–803. Epub 4 Jan 2001.
91. Marseille E, Kahn JG. Smarter programming of the female condom: increasing its impact on HIV prevention in the developing world. Published by FSG Social Impact Advisors, Available at http://www.fsg.org/Portals/0/Uploads/Documents/PDF/Female_Condom_Impact.pdf.
92. Kalichman SC, Williams E, Nachimson D. Brief behavioural skills building intervention for female controlled methods of STD-HIV prevention: outcomes of a randomized clinical field trial. *Int J STD AIDS*. 1999;10(3):174–81. Epub 26 May 1999.
93. Hoke TH, Feldblum PJ, Damme KV, Nasution MD, Grey TW, Wong EL, et al. Randomised controlled trial of alternative male and female condom promotion strategies targeting sex workers in Madagascar. *Sex Transm Infect*. 2007;83(6):448–53. Epub 27 June 2007.
94. Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they are infected with the virus in the USA. *AIDS*. 2006;20(10):1447–50. Epub 23 June 2006.
95. Phillips KA, Bayer R, Chen JL. New Centers for Disease Control and Prevention’s guidelines on HIV counseling and testing for the general population and pregnant women. *J Acquir Immune Defic Syndr*. 2003;32(2):182–91. Epub 7 Feb 2003.
96. Holtgrave D, McGuire J. Impact of counseling in voluntary counseling and testing programs for persons at risk for or living with HIV infection. *Clin Infect Dis*. 2007;45 Suppl 4:S240–3. Epub 8 Feb 2008.
97. Estrada BD, Trujillo S, Estrada AL. Supporting Healthy Alternatives through Patient Education: a theoretically driven HIV prevention intervention for persons living with HIV/AIDS. *AIDS Behav*. 2007;11(5 Suppl):S95–105. Epub 1 Feb 2007.
98. Metcalf CA, Malotte CK, Douglas Jr JM, Paul SM, Dillon BA, Cross H, et al. Efficacy of a booster counseling session 6 months after HIV testing and counseling: a randomized, controlled trial (RESPECT-2). *Sex Transm Dis*. 2005;32(2):123–9. Epub 26 Jan 2005.
99. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 infection. *N Engl J Med*. 2011;364(20):1943–54. Epub 20 May 2011.
100. Hightow-Weidman LB, Golin CE, Green K, Shaw EN, MacDonald PD, Leone PA. Identifying people with acute HIV infection: demographic features, risk factors, and use of health care among individuals with AHI in North Carolina. *AIDS Behav*. 2009;13(6):1075–83. Epub 8 Jan 2009.
101. Kelly JA, St Lawrence JS, Diaz YE, Stevenson LY, Hauth AC, Brasfield TL, et al. HIV risk behavior reduction following intervention with key opinion leaders of population: an experimental analysis. *Am J Public Health*. 1991;81(2):168–71. Epub 1 Feb 1991.
102. Kelly JA, St Lawrence JS, Stevenson LY, Hauth AC, Kalichman SC, Diaz YE, et al. Community AIDS/HIV risk reduction: the effects of endorsements by popular people in three cities. *Am J Public Health*. 1992;82(11):1483–9. Epub 1 Nov 1992.
103. Kelly JA, Murphy DA, Sikkema KJ, McAuliffe TL, Roffman RA, Solomon LJ, et al. Randomised, controlled, community-level HIV-prevention intervention for sexual-risk behaviour among homosexual men in US cities. *Community HIV Prevention Research Collaborative*. *Lancet*. 1997;350(9090):1500–5. Epub 6 Dec 1997.
104. Morin SF. AIDS: the challenge to psychology. *Am Psychol*. 1988;43(11):838–42. Epub 1 Nov 1988.
105. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O’Sullivan MJ, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. *Pediatric AIDS Clinical Trials Group Protocol 076 Study Group*. *N Engl J Med*. 1994;331(18):1173–80. Epub 3 Nov 1994.
106. Trust NA. HIV treatment as prevention. UK: National AIDS Trust; 2011.
107. Padian NS. Sexual histories of heterosexual couples with one HIV-infected partner. *Am J Public Health*. 1990;80(8):990–1. Epub 1 Aug 1990.
108. Cohen MS, Hoffman IF, Royce RA, Kazembe P, Dyer JR, Daly CC, et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of

- sexual transmission of HIV-1. AIDSCAP Malawi Research Group. *Lancet*. 1997;349(9069):1868–73. Epub 28 June 1997.
109. Steward WT, Remien RH, Higgins JA, Dubrow R, Pinkerton SD, Sikkema KJ, et al. Behavior change following diagnosis with acute/early HIV infection—a move to serosorting with other HIV-infected individuals. The NIMH Multisite Acute HIV Infection Study: III. *AIDS Behav*. 2009;13(6):1054–60. Epub 9 June 2009.
 110. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. *J Infect Dis*. 2005;191(9):1403–9.
 111. Mehta SD, Gray RH, Auvert B, Moses S, Kigozi G, Taljaard D, et al. Does sex in the early period after circumcision increase HIV-seroconversion risk? Pooled analysis of adult male circumcision clinical trials. *AIDS*. 2009;23(12):1557–64. Epub 3 July 2009.
 112. Cohen MS, Hosseinipour M. HIV treatment meets prevention: antiretroviral therapy as prophylaxis. In: M P, editor. *The AIDS pandemic: impact on science and society*. New York: Elsevier; 2004.
 113. Kalichman SC, Simbayi LC. Sexual exposure to blood and behavioural risks among STI clinic patients in Cape Town, South Africa. *Sex Health*. 2005;2(2):85–8. Epub 14 Dec 2005.
 114. Kalichman SC, Simbayi LC, Cain D, Cherry C, Jooste S. Coital bleeding and HIV risks among men and women in Cape Town, South Africa. *Sex Transm Dis*. 2006;33(9):551–7. Epub 12 May 2006.
 115. Kalichman SC, Cain D, Simbayi LC. Behavioral changes associated with testing HIV-positive among sexually transmitted infection clinic patients in Cape Town, South Africa. *Am J Public Health*. 2010;100(4):714–9. Epub 20 Feb 2010.
 116. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. *Lancet Infect Dis*. 2009;9(2):118–29. Epub 31 Jan 2009.
 117. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. *Lancet*. 2011;378(9787):256–68. Epub 21 June 2011.
 118. Coates TJ, Stall RD, Catania JA, Kegeles SM. Behavioral factors in the spread of HIV infection. *AIDS*. 1988;2 Suppl 1:S239–46. Epub 1 Jan 1988.
 119. Stall RD, Coates TJ, Hoff C. Behavioral risk reduction for HIV infection among gay and bisexual men. A review of results from the United States. *Am Psychol*. 1988;43(11):878–85. Epub 1 Nov 1988.
 120. Lescano CM, Houck CD, Brown LK, Doherty G, DiClemente RJ, Fernandez MI, et al. Correlates of heterosexual anal intercourse among at-risk adolescents and young adults. *Am J Public Health*. 2009;99(6):1131–6. Epub 15 Nov 2008.
 121. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15–44 years of age, United States, 2002. *Adv Data*. 2005;362:1–55. Epub 28 Oct 2005.
 122. Kalichman SC, Simbayi LC, Cain D, Jooste S. Heterosexual anal intercourse among community and clinical settings in Cape Town, South Africa. *Sex Transm Infect*. 2009;85(6):411–5. Epub 12 May 2009.
 123. Kalichman SC, Pinkerton SD, Carey MP, Cain D, Mehlomakulu V, Carey KB, et al. Heterosexual anal intercourse and HIV infection risks in the context of alcohol serving venues, Cape Town, South Africa. *BMC Public Health*. 2011;11:807. Epub 18 Oct 2011.
 124. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. *J Infect Dis*. 2004;190(5):879–85. Epub 6 Aug 2004.
 125. Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. *Sci Transl Med*. 2011;3(77):77ra29. Epub 8 Apr 2011.
 126. Pao D, Pillay D, Fisher M. Potential impact of early antiretroviral therapy on transmission. *Curr Opin HIV AIDS*. 2009;4(3):215–21. Epub 18 June 2009.

127. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. *AIDS*. 2009;23(11):1397–404. Epub 22 Apr 2009.
128. Hull MW, Montaner J. Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy. *Curr HIV/AIDS Rep*. 2011;8(2):85–93. Epub 30 Mar 2011.
129. Smith K, Powers KA, Kashuba AD, Cohen MS. HIV-1 treatment as prevention: the good, the bad, and the challenges. *Curr Opin HIV AIDS*. 2011;6(4):315–25. Epub 8 June 2011.
130. Cowan SA, Gerstoft J, Haff J, Hartvig Christiansen A, Statistician JN, Obel N. Stable incidence of HIV diagnoses among Danish MSM despite increased engagement in unsafe sex. *J Acquir Immune Defic Syndr*. 2012. Epub 18 May 2012.
131. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. *AIDS*. 2010;24(6):907–13. Epub 9 Feb 2010.
132. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. *Lancet*. 2009;373(9657):48–57. Epub 29 Nov 2008.
133. Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. *JAMA*. 2009;301(22):2380–2. Epub 11 June 2009.
134. Hallett TB, Smit C, Garnett GP, de Wolf F. Estimating the risk of HIV transmission from homosexual men receiving treatment to their HIV-uninfected partners. *Sex Transm Infect*. 2011;87(1):17–21. Epub 21 July 2010.
135. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. *Curr Opin HIV AIDS*. 2012;7(2):99–105. Epub 10 Jan 2012.
136. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. *N Engl J Med*. 2011;365(6):493–505. Epub 20 July 2011.
137. Cohen MS, Gay CL. Treatment to prevent transmission of HIV-1. *Clin Infect Dis*. 2010;50 Suppl 3:S85–95. Epub 20 Apr 2010.
138. Vernazza PL, Eron JJ, Cohen MS, van der Horst CM, Troiani L, Fiscus SA. Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. *AIDS*. 1994;8(9):1325–9. Epub 1 Sept 1994.
139. Vernazza PL, Gilliam BL, Flepp M, Dyer JR, Frank AC, Fiscus SA, et al. Effect of antiviral treatment on the shedding of HIV-1 in semen. *AIDS*. 1997;11(10):1249–54. Epub 1 Aug 1997.
140. Vernazza PL, Troiani L, Flepp MJ, Cone RW, Schock J, Roth F, et al. Potent antiretroviral treatment of HIV infection results in suppression of the seminal shedding of HIV. *AIDS*. 2000;14(2):117–21.
141. Vernazza P, Hirschel B, Bernasconi E, Flepp M. HIV-positive individuals without additional sexually transmitted diseases (STD) and on effective anti-retroviral therapy are sexually non-infectious. *Bulletin des medecins suisses* 2008;89(5):165–9.
142. Strub S. Swiss say condoms not necessary...sometimes. *Huffington Post*, March 26, 2008. Available at http://www.huffingtonpost.com/sean-strub/swiss-say-condoms-not-nec_b_93574.html.
143. WHO-UNAIDS. Antiretroviral therapy and sexual transmission of HIV. UNAIDS, Geneva, Switzerland. Available at http://data.unaids.org/pub/pressstatement/2008/080201_hivtransmission_en.pdf.
144. Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute-phase HIV transmission? *AIDS*. 2007;21(12):1625–9. Epub 17 July 2007.
145. Cohen MS. HIV treatment as prevention and “the Swiss statement”: in for a dime, in for a dollar? *Clin Infect Dis*. 2010;51(11):1323–4. Epub 3 Nov 2010.
146. Kalichman SC, Di Berto G, Eaton L. Human immunodeficiency virus viral load in blood plasma and semen: review and implications of empirical findings. *Sex Transm Dis*. 2008;35(1):55–60. Epub 25 Jan 2008.

147. Hosein S, Wilson D. Decision-making by people living with HIV requires communication from clinicians about the risks of transmission despite undetectable plasma viral load. *HIV Med.* 2010;12:516.
148. Kalichman SC, Cage M, Barnett T, Tharnish P, Rompa D, Austin J, et al. Human immunodeficiency virus in semen and plasma: investigation of sexual transmission risk behavioral correlates. *AIDS Res Hum Retroviruses.* 2001;17(18):1695–703. Epub 15 Jan 2002.
149. Cu-Uvin S, Hogan JW, Caliendo AM, Harwell J, Mayer KH, Carpenter CC. Association between bacterial vaginosis and expression of human immunodeficiency virus type 1 RNA in the female genital tract. *Clin Infect Dis.* 2001;33(6):894–6. Epub 21 Aug 2001.
150. Vernazza P, Kashuba A, Cohen MS. Biological correlates of sexual transmission of HIV: practical consequences and potential targets for public health. *Rev Med Microbiol.* 2001;12(3):131–42.
151. Reichelderfer PS, Coombs RW, Wright DJ, Cohn J, Burns DN, Cu-Uvin S, et al. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract WHS 001 Study Team. *AIDS.* 2000;14(14):2101–7. Epub 4 Nov 2000.
152. Kalichman SC, Eaton L, Cherry C. Sexually transmitted infections and infectiousness beliefs among people living with HIV/AIDS: implications for HIV treatment as prevention. *HIV Med.* 2010;11(8):502–9. Epub 6 Mar 2010.
153. Kalichman SC, Rompa D, Austin J, Luke W, DiFonzo K. Viral load, perceived infectivity, and unprotected intercourse. *J Acquir Immune Defic Syndr.* 2001;28(3):303–5. Epub 6 Nov 2001.
154. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. *Clin Infect Dis.* 2010;51(11):1314–22. Epub 3 Nov 2010.
155. Johnson LF, Lewis DA. The effect of genital tract infections on HIV-1 shedding in the genital tract: a systematic review and meta-analysis. *Sex Transm Dis.* 2008;35(11):946–59. Epub 8 Aug 2008.
156. Kalichman SC, Pellowski J, Turner C. Prevalence of sexually transmitted co-infections in people living with HIV/AIDS: systematic review with implications for using HIV treatments for prevention. *Sex Transm Infect.* 2011;87(3):183–90. Epub 19 Feb 2011.
157. Holtgrave DR, Maulsby C, Wehrmeyer L, Hall HI. Behavioral factors in assessing impact of HIV treatment as prevention. *AIDS Behav.* 2012;16(5):1085–91. Epub 12 Apr 2012.
158. Holtgrave DR, Hall HI, Wehrmeyer L, Maulsby C. Costs, consequences and feasibility of strategies for achieving the goals of the National HIV/AIDS Strategy in the United States: a closing window for success? *AIDS Behav.* 2012. Epub 23 May 2012.
159. Kurth AE, McClelland L, Wanje G, Ghee AE, Peshu N, Mutunga E, et al. An integrated approach for antiretroviral adherence and secondary HIV transmission risk-reduction support by nurses in Kenya. *J Assoc Nurses AIDS Care.* 2012;23(2):146–54. Epub 2 Aug 2011.
160. Ewart C. Social action theory for a public health psychology. *Am Psychol.* 1991;465:931–46.
161. Ewart C. How integrative behavioral theory can improve health promotion and disease prevention. In: Boll TJ, Frank RG, Baum A, Wallander J, editors. *Handbook of health psychology.* Washington, DC: American Psychological Association; 2004.
162. Gore-Felton C, Rotheram-Borus MJ, Weinhardt LS, Kelly JA, Lightfoot M, Kirshenbaum SB, et al. The Healthy Living Project: an individually tailored, multidimensional intervention for HIV-infected persons. *AIDS Educ Prev.* 2005;17(1 Suppl A):21–39. Epub 22 Apr 2005.
163. Chesney MA, Chambers DB, Taylor JM, Johnson LM, Folkman S. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. *Psychosom Med.* 2003;65(6):1038–46. Epub 4 Dec 2003.
164. Chesney M, Folkman S, Chambers D. Coping effectiveness training for men living with HIV: preliminary findings. *Int J STD AIDS.* 1996;7 Suppl 2:75–82. Epub 1 Jan 1996.

165. Healthy Living Project Team. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. *J Acquir Immune Defic Syndr*. 2007;44(2):213–21. Epub 6 Dec 2006.
166. Johnson MO, Charlebois E, Morin SF, Remien RH, Chesney MA. Effects of a behavioral intervention on antiretroviral medication adherence among people living with HIV: the healthy living project randomized controlled study. *J Acquir Immune Defic Syndr*. 2007;46(5):574–80. Epub 15 Jan 2008.
167. Pinkerton SD, Holtgrave DR, Valdiserri RO. Cost-effectiveness of HIV-prevention skills training for men who have sex with men. *AIDS*. 1997;11(3):347–57. Epub 1 Mar 1997.
168. Pinkerton SD, Holtgrave DR. How HIV treatment advances affect the cost-effectiveness of prevention. *Med Decis Making*. 2000;20(1):89–94. Epub 19 Jan 2000.
169. Prochaska JO, Velicer WF. The transtheoretical model of health behavior change. *Am J Health Promot*. 1997;12(1):38–48. Epub 5 Aug 1997.
170. Miller WR, Rose GS. Toward a theory of motivational interviewing. *Am Psychol*. 2009;64(6):527–37. Epub 11 Sept 2009.
171. Holstad M, DiIorio C, Magowe M. Motivating HIV positive women to adhere to antiretroviral therapy and risk reduction behavior: The KHARMA Project. *J Issues Nurs*. 2006; 11:1–19.
172. Holstad MM, DiIorio C, Kelley ME, Resnicow K, Sharma S. Group motivational interviewing to promote adherence to antiretroviral medications and risk reduction behaviors in HIV infected women. *AIDS Behav*. 2011;15(5):885–96. Epub 18 Nov 2010.
173. Kalichman SC, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. *Am J Public Health*. 2011;101(3):531–8. Epub 15 Jan 2011.
174. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, et al. HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. *Am J Public Health*. 2005;95(8): 1439–1445.

Index

A

Abstinence, Be faithful, and Condoms (ABCs), 41
Abstinence only sex education programs, 40, 41
Adherence, 24, 77
 intervention, 20–21
 medication, 58, 86–87
Adolescents, HIV risk behaviors in, 21
AIDS Clinical Trial Group protocol, 61
AIDS prevention. *See* HIV prevention
AIDS risk reduction workshop, 2
American Academy of Pediatrics, 33
American Association of Public Health Association, 33
American Bar Association, 33
American Medical Association, 33
American Nurses Association, 33
Amico, Rivet, 20, 21
Anal sex, and HIV infection, 28, 65–67
Antiretroviral therapy, 1, 2, 28, 61, 67, 68, 77, 85
Arizona, evidence-based prevention programs in, 55
Association of State and Territorial Health Officials, The, 33

B

Bacterial vaginosis, 81
Baeten, Jared, 64
Bangsberg, David, 6
Behavioral inoculation, 8

Behavioral intervention(s), 26
 biomedical technologies, 57–58
 brief interventions, 25
 computerized interventions, 26
 and HIV prevention, 1–4–6, 9–10
 adherence intervention, 20–21
 Consensus Panel, 3
 Thailand, condom campaign in, 3
 in Uganda, 3–4
 intensive behavioral interventions, 35
 and TasP, 83
 Healthy Living Project, 83–86
 In The Mix, 87–90
 risk reduction and medication adherence, 86–87
Behavioral principles, for TasP, 21
 adherence, 24
 adolescents, HIV risk behaviors in, 21
 briefer behavioral interventions, 25
 common principles, 22
 computerized interventions, 25–26
 partial protection, 23
 “programs in a box” approach, 21
 risk compensation, 23–24
 Risk Homeostasis Theory, 24
 Self-Regulation Theory, 26–27
 teachable moments, 27–28
 Wise-pill, usage of, 27
Behavior trumps biology, 6–8
Beliefs trump behavior, 79–81
Be Proud–Be Responsible program, 41
Biological prevention technology, 2

- Biomedical (prevention)
 technology, 6–7, 57–58
- Bush, George W., 41
- Butler, David, 64
- C**
- Carballo-Diequez, Alex, 56
- Cellular level, HIV prevention at, 4–6
- Chesney, Margaret, 13
- China, condom distribution in, 45
- Chlamydia, 26, 81
- Client-centered counseling, 51–55
- Clinton, Bill, 40
- Coates, Tom, 19, 28, 66
- Cohen, Mike, 57, 65
- Combination HIV prevention (UNAIDS), 28
- Community Demonstration Projects
 (CDC), 91
- Community level, HIV prevention at, 4–6
- Condom(s), 37
 counseling, 41–42
 desensitization, 42
 distribution and STI rates, 42
 double standards, 44
 failure, 38
 female, 45–47
 Futura, 39
 latex, 39
 male, 37–39
 negative attitude, 38
 politics, 39–41
 polyurethane, 39
 shortages, 45
 spray-on, 39
 successes, 42–44
- 100% condom campaign (Thailand), 3, 42
- Confidentiality, 94
- Conflict Theory of Decision Making, 88
- Consensus Panel, 3
- Contraceptive condom failures, 38
- Coping Effectiveness Training, 84
- Crepaz, Nicole, 79
- Crosby, Rick, 38
- D**
- de Bruin, Marijn, 20
- Des Jarlais, Don, 32, 35
- Dieffenbach, Carl, 70
- DiIorio, Colleen, 20–21, 86
- Dyadic level, and HIV prevention, 4–6
- E**
- Eaton, Lisa, 9, 27
- Eban Trial, 6
- Ewart, Craig, 83
- F**
- Family level, HIV prevention at, 4–6
- Fauci, Anthony, 70
 Female condoms, 45–47.
See also Condom(s)
 international shipments, 45
 shortages, 45
- Female Health Company, 46
- Fishbein, Martin, 7
- Fisher, Jeff, 26
- Friedman, Sam, 36
- Futura, 39
- G**
- Gable, Alicia, 9, 10
- Gay Men’s Health Crisis, 2
- Gay Pride event (Atlanta), 67
- Genital fluids, HIV in, 68, 81
- Genital ulcers, 64–66
- Global condom market, 45
- Goffman, Erving, 59
- Gonorrhea, 3, 9, 11, 26, 67, 81
- Gore-Felton, Cheryl, 84
- Granich, Reuben, 70
- Grimley, Diane, 26
- H**
- Haberer, Jessica, 27
- Harm Reduction Coalition, 34
- Harm reduction perspective, and TasP, 59
- HCV. *See* Hepatitis C virus (HCV)
- Healthy Living Intervention, 83, 85
- Healthy Living Project, 83–86
- Heimer, Robert, 33
- Hepatitis C virus (HCV), 32
- Hightow-Weidman, Lisa, 57
- HIV antibody testing, 1
 client-centered counseling, 51–55
 diagnostic testing, 47–49
 guidelines, 52
 new testing technologies, 55–57
 Project Respect, 49–51
 and TasP, 59
 technologies, 55–57

- HIV infection
 - acute, 76
 - antibody testing (*see* HIV antibody testing)
 - prevention (*see* HIV prevention)
 - public health detection, 57
 - sexual reproductive rate, 7
 - susceptibility, 63, 65–66
 - transmission (*see* HIV transmission)treatment, 67–68
- HIV prevention
 - AIDS risk reduction workshop, 2
 - antiretroviral therapy, 1, 2, 28, 61, 67, 68, 77, 85
 - behavioral intervention(s), 1–4, 9
 - adherence intervention, 20–21
 - behavioral prevention, 9–10
 - behavior trumps biology, 6–8
 - biological prevention technology, 2
 - cellular level, 4–6
 - common principles, 22
 - community level, 4–6
 - condoms, 37–47
 - diagnostic testing, 1
 - dyadic level, 4–6
 - Eban Trial, 6
 - family level, 4–6
 - future, 91–92
 - Gay Men’s Health Crisis, 2
 - HIV antibody testing (*see* HIV antibody testing)individual behavior, 4–6
 - institution level, 5
 - intervention trials, 8
 - lessons learned
 - biomedical technologies, into
 - behavioral interventions, 57–58
 - harm reduction perspective, and TasP, 59
 - HIV testing, and TasP, 59
 - medication adherence, 58
 - social support, and TasP, 58–59
 - stigma research, and TasP, 59
 - STI risks, 58
 - MIRA Trial, 10–13
 - needles and syringes, 31–37
 - network level, 4–6
 - prevention revolution, 1, 2
 - Project Explore, 13–20
 - Project Light, 8
 - risk reduction
 - counseling, 2, 3
 - interventions, 8–9
 - single session interventions, 9
 - skills building workshops, 2
 - STI treatments, 4–6
 - Stop AIDS San Francisco, 2
 - structural level, 5
 - synergism, 2
 - treatment as prevention (TasP)
 - behavioral principles, 21–28
 - theoretical framework, 28–29
 - HIV prevention budget (CDC), 48, 49
 - HIV Prevention Trials Network (HPTN), 71–73
 - HIV Testing Guidelines (2006), 54
 - HIV transmission
 - risk behaviors, 63, 66–67
 - treatment, impact of, 69–70
 - and viral load, 68
 - Hoke, Theresa, 47
 - Holmes, King, 28
 - Holstad, Marcia McDonnell, 86
 - Holtgrave, David, 50, 54, 55, 82
 - HPTN. *See* HIV Prevention Trials Network (HPTN)
 - Human papillomavirus (HPV)
 - vaccination, 58, 81
- I**
 - Individual behavior, and HIV
 - prevention, 4–6
 - Infectiousness beliefs and sexual risk
 - behaviors, 79–80
 - Infectivity
 - factors, 62
 - host susceptibility, 65–66
 - risk behaviors, 66–67
 - source infectiousness, 63–65
 - Injection drug users
 - social interventions for, 35–37
 - in USA, 31
 - Institution level, HIV prevention at, 5
 - Intensive behavioral interventions, 35
 - International AIDS Society (2011), 35
 - Interventions to Prevent HIV Risk
 - Behaviors, 7
 - In The Mix
 - behavioral interventions with TasP, 87–90
 - intervention manual, 93–116
 - alcohol and other substance use, decisional balance of, 111
 - ARV video-HIV resistance, 101–102
 - biggest mess video, 110
 - brainstorm moods and strategies, 113
 - brainstorm strategies activity, 111
 - buzz in community, 96

- In The Mix (*cont.*)
 condom use, decisional balance
 for, 115
 cue cards, 95
 DeAndre and Martin video, 108–109
 decisional balance of coming
 to group, 98
 Dr. Smith and Roy video clip, 106–107
 Family Feud game, 97–98, 112–113
 group members introduction, 94
 group rules, 94
 Hands on Virus, 102
 Harry's decisional balance, 104
 HIV medication decisional
 balance, 103
 housekeeping, 94–95
 impaired glasses, 112
 MAPS, 105, 114
 married man (situation influence),
 109–110
 Marta's decisional balance, 104
 Marta's scenario, 103
 movie clip-boat trip, 98–99
 myths and facts, 100–101
 participant condom demonstration,
 115–116
 Pat's MAPS scenario cards, 107–108
 relaxation exercise, 114
 review session, 99
 shopping, 116
 STD puppet video, 115
 undetectable viral load, 103
 video bad boys clip, 114
- J**
 Jackson Lee, Sheila, 34
 Jemmott, John, 41
 Joint United Nations Programme on
 HIV/AIDS (UNAIDS), 74, 75
Journal of Test Positive Aware Network, 102
- K**
 Kaplan, Edward, 33
 Kelly, Jeff, 38, 59
 KHARMA intervention, 86–87
 Koblin, Beryl, 13
 Koop, C. Everett, 39, 41
- L**
 Lagakos, Stephen, 9, 10
 Latex condom, 39. *See also* Condom(s)
- Latkin, Carl, 35, 59
 Little, Susan, 64
- M**
 Male condoms, 37–39. *See also* Condom(s)
 MAPS. *See* Moods, Alcohol and other
 substances, People, and Situations
 (MAPS)
 Medication adherence, 58, 83, 85, 89.
 See also Adherence
 computerized program, 26
 improvements, 20–21
 and risk reduction, 86–87
 Merson, Mike, 3, 42
 Metcalf, Carol, 55
 MIRA project intervention protocol, 11
 MIRA Trial, 10–13
 HIV incidence, 12–13
 MIRA project intervention protocol, 11
 safer sex counseling script, 11–12
 Moods, Alcohol and other substances,
 People, and Situations (MAPS),
 105–108, 114
 Morin, Stephen, 59
 Motivational Enhancement Therapy, 86
 Motivational interviewing adherence
 intervention, 20–21
- N**
 National Academy of Sciences, 33
 National AIDS Trust Panel (UK), 62
 National Institute on Drug Abuse Cooperative
 Agreement, 91
 National Institutes of Health (NIH), 2
 Needle(s)
 exchange programs, 33–34
 and syringes, 31
 social interventions for injection drug
 users, 35–37
 syringe access, 32–35
 Network level interventions, and HIV
 prevention, 4–6
 NIH. *See* National Institutes of Health (NIH)
 NIH Consensus Development Conference, 7,
 33, 40
 Noar, Seth, 8
- O**
 Obama, Barack, 34
 Oral sex, and HIV infection, 67
 Overbaugh, Julie, 64

P

- Padian, Nancy, 10, 11, 62, 65
- Parianti, Jean-Jacques, 20
- Patterson, Tom, 44
- Pelosi, Nancy, 34
- Peterman, Tom, 55
- Phillips, Ross, 23
- Pinkerton, Steve, 34
- Plasma viral load and sexual infectiousness, 77–79
- Politics of condoms, 39–41
- Politics of syringe access, 33–35
- Polyurethane condoms, 39. *See also* Condom(s)
- Prevention revolution, 1, 2
- Project Explore, 13–20
 - counseling and control conditions, 17–18
 - HIV incidence, 15–17, 19–20
 - modules, themes, and session descriptions, 14
 - vaccine preparedness studies (VPS), 15
- Project Light, 8
- Project Respect, 49–51
- Public Health Service Act, 40

R

- Reiss, David, 33
- Reynolds, Nancy, 26
- Riggs, Frank, 34
- Rio Community Health Center, 55
- Risk behaviors, 63, 66–67
- Risk Homeostasis Theory, 24
- Risk reduction
 - counseling, 1–3, 6, 9, 11, 15, 21, 25, 26, 31, 41, 48, 49, 51, 53–56, 68, 69, 91
 - interventions, 8–9
 - and medication adherence, 86–87
- Rotheram-Borus, Mary Jane, 21, 22
- Russia, HIV epidemic in, 34

S

- Safer sex counseling script, 11–12
- Scott-Sheldon, Lori, 9
- Self-Help in Eliminating Life-Threatening Diseases (SHIELD), 35, 36
- Self-Regulation Theory, 26–27
- Sex education, 39, 40
- Sexual infectiousness, and plasma viral load, 77–79
- Sexually transmitted coinfections, 81–82
- SHARE Project, 93, 97, 112–113

SHIELD. *See* Self-Help in Eliminating Life-Threatening Diseases (SHIELD)

- Simoni, Jane, 20
- Single session interventions, 9
- Slutkin, Gary, 3
- Social Action Theory (Craig Ewart), 83
- Social interventions, for injection drug users, 35–37
- Social support, and TasP, 58–59
- Source infectiousness, 63–65
- South Africa
 - condom distribution in, 45
 - HIV epidemic in, 37
 - STI clinics, 55
- South African Department of Health, 38
- Spray-on condom, 39. *See also* Condom(s)
- Stages of Health Behavior Change Model, 26
- Stall, Ron, 16, 66
- Stand-alone adherence interventions, 21
- Stigma research, and TasP, 59
- STI risks, and TasP, 58
- STI Treatment Guidelines (2006), 54
- STI treatments, 4–6
- Stop AIDS San Francisco, 2
- Strub, Sean, 74
- Structural interventions, and HIV prevention, 5
- Swiss National AIDS Commission (EKAF), 73
- Swiss Statement, 73–75
- Syphilis, 81
- Syringe
 - access, 32–35
 - exchange programs, 35

T

- Tadesse, Wuhib, 4
- TasP. *See* Treatment as prevention (TasP)
- Tatoud, Roger, 28, 61
- Taylor, Darien, 74
- Teachable moments, features of, 27
- “Test and treat” strategy, 59
- Thailand
 - 100% condom campaign, 3, 42
 - condom distribution, social policy for, 42–43
 - HIV incidence, 44
- Theoretical framework, for TasP, 28–29
- Time-matched non-sexual health program, 41
- Transtheoretical Model of Behavior Change, 86
- Treatment Action Campaign, 38

- Treatment as prevention (TasP), 61
 assumptions, 76
 behavioral interventions, 83
 Healthy Living Project, 83–86
 In The Mix, 87–90
 risk reduction and medication
 adherence, 86–87
 behavioral principles, 21–28
 failure, 75
 acute HIV infection, 76
 adherence, 77
 beliefs trump behavior, 79–81
 plasma viral load and sexual
 infectiousness, 77–79
 sexually transmitted coinfections, 81–82
 harm reduction perspective, 59
 HIV prevention, future of, 91–92
 HIV Prevention Trials Network (HPTN),
 71–73
 HIV testing, 59
 HIV treatment, 67–68
 implementation, 82
 infectivity triad, 62
 host susceptibility, 65–66
 risk behaviors, 66–67
 source infectiousness, 63–65
 mathematical models, 70–71
 preventive benefits, 79
 Rakai findings, 68–70
 risk compensation, 79
 social support, 58–59
 stigma research, 59
 Swiss Statement, 73–75
 theoretical framework, 28–29
 Trichomoniasis, 81
- U**
- Uganda
 HIV prevention, 3–4
 HIV transmission, 63, 64
 UK, National AIDS Trust Panel in, 62
 Ukraine, HIV infections in, 34
 United Nations Population Fund, 45
 USA
 condoms, sale of, 45
 contraceptive condom failures, 38
 injection drug users in, 31
 US Conference of Mayors, The, 33
 US National HIV/AIDS Strategy, 82
- V**
- Vaccine preparedness studies (VPS), 15
 Vaginal sex, and HIV infection, 62, 65–67,
 77, 84
 Ventuneac, Ana, 56
 Vernazza, Pietro, 73
 Vlahov, David, 33
 VPS. *See* Vaccine preparedness
 studies (VPS)
- W**
- Weinhardt, Lance, 25, 53
 Wingood, Gina, 44
 Wise-pill, usage of, 27
 World Health Organization (WHO), 74, 75
- Z**
- Zimbabwe, female condom usage in, 47